Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage
Arcus Biosciences shares rose 4.8% to $22.32 Tuesday after Goldman Sachs upgraded the stock to “Buy” and raised its price target. The move followed early Phase 1 data for lead drug casdatifan showing response rates of 31% alone and 46% in combination for advanced kidney cancer. Arcus plans to present at the J.P. Morgan Healthcare Conference on Wednesday. The company reported $1 billion in cash and funding into late 2028.
